TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors [Yahoo! Finance]
TransCode Therapeutics, Inc. (RNAZ)
Company Research
Source: Yahoo! Finance
the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee. Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation. "We are delighted to welcome Jack to TransCode's Board of Directors," said Philippe P. Calais, CEO, TransCode Therapeutics. "Jack's wide and unique operational, financial, and strategic expertise — as well as his successes leading through transformative growth — will be a powerful asset as TransCode advances its RNA and immuno-oncology pipeline." Mr. Stover currently serves as Chairman of the Board of Traws Pharma Inc., a specialty pharmaceutical company focused on anti-virals and oncology. He led the merger of Traws with Onconova Th
Show less
Read more
Impact Snapshot
Event Time:
RNAZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNAZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNAZ alerts
High impacting TransCode Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RNAZ
News
- TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of DirectorsPR Newswire
- TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trialPR Newswire
- TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer [Yahoo! Finance]Yahoo! Finance
- TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development OfficerPR Newswire
- TransCode Therapeutics (NASDAQ:RNAZ) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
RNAZ
Sec Filings
- 12/23/25 - Form EFFECT
- 12/22/25 - Form 3
- 12/22/25 - Form 3
- RNAZ's page on the SEC website